SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.410
-0.130 (-8.44%)
At close: May 13, 2025, 4:00 PM
1.496
+0.086 (6.11%)
Pre-market: May 14, 2025, 8:42 AM EDT
SLS Employees
SELLAS Life Sciences Group had 15 employees as of December 31, 2024. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,808,533
Market Cap
128.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLS News
- 16 hours ago - SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 16 days ago - SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - GlobeNewsWire
- 20 days ago - SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 5 weeks ago - SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewsWire
- 6 weeks ago - Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst - Seeking Alpha
- 7 weeks ago - SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire